Zarzio filgrastim regulatory update

FDA approved a BLA for Zarxio from Novartis’ Sandoz Inc. generics unit, a biosimilar of neutropenia drug Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.).

Read the full 265 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE